I nflammatory bowel disease (IBD) is a chronic, incurable inflammatory disorder of the intestinal tract. It is believed to occur as a result of a complex interplay between an individual's genetics and their environment (1) . Left untreated, IBD can lead to profound morbidity, with impaired health-related quality of life and time away from work (2, 3) . Complications of the disease result in the need for prolonged hospitalizations and surgical intervention (4) (5) (6) . Studies of resource use in IBD suggest that the economic burden associated with the direct costs of surgery and hospitalization is substantial (7, 8) .
There have been rapid advancements in the understanding of disease pathogenesis and the development of therapeutic agents used to treat IBD during the past decade. Biological agents such as infliximab (a monoclonal antibody directed against tumour necrosis factor [TNF]-alpha) have been demonstrated in randomized controlled trials (RCTs) to have the highest rates of clinical efficacy of any therapeutic agent to date (9, 10) . However, infliximab is expensive and has been shown to be associated with some rare but potentially serious adverse events within the context of clinical trials, postmarketing surveillance programs and treatment registries. Clinical and pharmacokinetic studies have reported the optimal dose range and interval regimen for the administration of infliximab (9) (10) (11) . Deviation from these clinical protocols has been shown to be associated with increased rates of infusion reactions and loss of response to the medication due, in part, to the development of immunogenicity. This has prompted the publication of consensus guidelines by many IBD organizations in several different countries (12) .
Little research determining how clinicians use biological agents in real-world clinical practice has been performed. Similarly, the medical literature has very little information about the factors that influence patterns of infliximab use among gastroenterologists who treat patients with IBD. This information is essential to facilitate a better understanding of the continuing medical education (CME) needs of the gastroenterology community. Such information can also assist policy makers in regional and national health care planning and resource distribution. In Canada, medication costs are not covered under the BaCkGRound: Little is known about physician perceptions of and practices in using infliximab -a biological agent that was approved in Canada for the treatment of Crohn's disease in 2001, and for ulcerative colitis in 2006. oBJeCtives: To describe Canadian gastroenterologists' use and perceptions of infliximab in the treatment of refractory inflammatory bowel disease (IBD), and to identify factors that may influence a gastroenterologist's decision to initiate infliximab therapy. MetHods: A postal questionnaire was distributed to all practicing clinicians captured in the 2007 membership of the Canadian Association of Gastroenterology. Each physician was contacted up to a maximum of three times. ResuLts: Of 466 questionnaires mailed out, responses were received from 336 (72%), with 292 respondents (63%) returning fully completed surveys. For 80% of respondents, IBD patients comprised less than 30% of their clinical practice. Most prescribed infliximab at an initial dose of 5 mg/kg (97%), prescribed loading doses at 0, 2 and 6 weeks (88%), premedicated with corticosteroids (74%), administered maintenance infusions at eight-week intervals (89%), co-administered immunosuppressive agents (81%) and continued infliximab 'indefinitely' as long as it was effective and well tolerated (76%). Most gastroenterologists (>70%) identified lack of drug insurance coverage and provincial funding criteria as important barriers to prescribing infliximab. ConCLusions: Most Canadian gastroenterologists exhibited similar practice patterns with respect to the use of infliximab for induction and maintenance therapy of IBD. Common barriers to the initiation of infliximab therapy were identified. universal health care system. Patients often carry private, personal insurance to cover the costs of their medications. Each province exercises its own discretion in deciding whether to subsidize the cost of a medication. Costly medications, such as infliximab, are considered special medications and patients must fulfill a specific set of criteria (ie, exceptional health status) to be considered for medication coverage by each province.
The objectives of the present study were to describe the clinical patterns of infliximab use for the treatment of medically refractory IBD by Canadian physicians involved in the medical treatment of patients with IBD, and to determine whether practice-or physician-related factors, demographic factors, method of CME or region of practice influence patterns of infliximab use. 
MetHods

Questionnaire development
A postal questionnaire was developed and administered according to the principles of Choi and Pak (14) to minimize bias, as well as the tailored design principles of Dillman (15) . The questions were scenario based and closed ended (Table 1) . Questions were designed to evaluate clinical patterns of infliximab use in the treatment of medically refractory IBD, as well as drug-related and nonpharmacological factors that might influence the decision to prescribe infliximab. Specific practice patterns of interest pertained to the following: whether physicians use infliximab; the dose of infliximab used; how often and at what interval infliximab is given; whether physicians administer other immunosuppressants (IS) with infliximab; whether physicians use corticosteroids as premedication with infliximab; how long physicians treat patients with infliximab; and what physicians do when patients lose response to infliximab. The practice-and physicianrelated factors evaluated included the following: proportion of IBD patients in clinical practice; type of practice (academic versus community); years in practice; and province in which the physician practiced. In addition, specific inquiry regarding the impact of specific barriers to infliximab use was made.
Pilot testing was undertaken among a small group of eight local gastroenterologists including community-based (n=2) and academic gastroenterologists (n=3), as well as gastroenterology trainees (n=3). Pilot testing was performed by distributing the questionnaire to these individuals. These individuals were then met with separately to discuss identified design flaws, and to ensure comprehensibility and appropriateness of content and format. The motivational quality (level of interest to the respondent) of the questionnaire was also evaluated to increase the likelihood of survey completion and to minimize item nonresponse. Five of these gastroenterologists were subsequently involved in the main survey.
Questionnaire distribution
Standard letter mail was used to contact the participants. Several evidence-based techniques proven to maximize response rates to mail surveys were used (14, 15) . Survey distribution consisted of four mailouts ( Figure 1) . A brief prenotification letter preceded the first questionnaire by four days. A nonconditional incentive in the form of a gift certificate valued at $15 from a national bookstore chain was included with the initial questionnaire. Final analysis was performed using data from questionnaires received within three months of the final questionnaire mailout. Individuals who did not wish to complete the questionnaire or who were not eligible to do so were asked to return an abbreviated 'refuser/not eligible' questionnaire that posed the following seven questions: 
statistical analysis
Final analysis was performed using data from questionnaires received within three months of the final questionnaire mailing. Responders were classified as 'early' or 'late' to determine whether there were systematic differences between the characteristics of early versus late respondents (assuming the late respondents were similar in nature to nonrespondents) to assess nonresponse bias.
A precision-based estimate of sample size was calculated, with 210 completed respondent questionnaires required to provide an acceptable sampling error (approximately 5%) and a 95% CI for the obtained point estimate(s) (15) . Thus, a response rate of 45% was required to ensure precision of the survey responses. All data analysis was descriptive. Response rates were calculated by dividing the number of respondents by the total number of participants to whom the survey was distributed (a denominator of 466). Group comparisons of the proportion of responses to each questionnaire item were performed using c 2 analysis or Fisher's exact test. Means, SDs and ranges of responses were presented, with 95% CIs constructed for all point estimates. The alpha for statistical testing was set at 5% for each questionnaire item. All data analysis was performed using Stata SE version 9.0 (Stata Corporation, USA).
ResuLts
Response rate
The overall response rate (including completed questionnaires and those returning nonresponse forms) was 72% (336 of 466) ( Table 2) . Sixty-three per cent returned completed questionnaires (292 of 466). More than two-thirds were early responders (those returning a completed questionnaire within two weeks of the second mailing). A total of 9.4% (44 of 466) returned 'refuser/not eligible' questionnaires and were deemed ineligible for the survey. Thus, the response rate among those eligible for the survey was 79.6% (336 of 422). Item response was very high (98% [287 of 292]).
Respondent characteristics
The demographic characteristics of the respondents are summarized in Table 3 . More than two-thirds of respondents were older than 44 years of age, and almost 70% had been in clinical practice for more than a decade (Table 3) . Fifty-three per cent self-reported having an academic practice, and the majority of respondents' practices consisted of more than 50% clinical practice. Only 10% of respondents described a clinical caseload of more than 50% IBD.
Patterns of infliximab use
The vast majority of respondents identified medically refractory IBD, fistulizing Crohn's disease (CD) and steroid-dependent CD as indications for infliximab use (Table 4) . Fewer gastroenterologists recognized pyoderma gangrenosum, ankylosing spondylitis or new, severely active CD as an indication for infliximab use (Table 4 ). There was consistency in the regimens for using infliximab: 97% started with a dose of 5 mg/kg; 88% used a three-dose induction regimen; and 89% provided maintenance infusions at eight-week intervals (Table 5) . Three-quarters (75%) used steroids as premedication before infliximab infusions, 80% co-administered IS with infliximab, 77% indicated that they would continue infliximab indefinitely provided that it was effective and well tolerated, and 76% indicated that they would decrease the infliximab interval if a patient exhibited loss of response to the drug, presumably as a result of immunogenicity.
influence of practitioner-and practice-related factors on patterns of infliximab use
Physicians with academic practices differed from those with primarily community practices with respect to the concomitant administration of IS and the strategy used on loss of response to infliximab. Of the respondents who indicated that they did not co-administer IS with infliximab, 72% (32 of 47) were in academic practice compared with 13% (28 of 47) in community practice (P<0.01). Respondents in academic practice were more likely to continue infliximab for one year (as opposed to three months, six months or indefinitely) as long as the drug was well tolerated and effective, compared with respondents in community practice (67% versus 33% [P<0.05]). Physician age, number of years in clinical practice, proportion of case mix consisting of IBD and proportion of clinical work performed were not associated with differences in how respondents used infliximab.
influence of practice region on patterns of infliximab use
Response distributions were stratified according to the region in which a clinician practiced: western Canada, Ontario, Quebec or Atlantic Canada. A larger proportion of clinicians in western Canada administered infliximab induction doses as a single infusion or as two infusions at weeks 0 and 4. Practice region was not associated with any other aspect of practice pattern. 
Barriers to infliximab use
All of the following factors were considered to represent major barriers to the prescribing of infliximab by the majority of respondents: drug cost, personal insurance coverage, provincial funding criteria, the absence of infusion facilities and lack of trained personnel to administer infliximab. More than 50% of respondents identified drug cost as being an important factor to consider when deciding to initiate infliximab infusions (0.52 [95% CI 0.46 to 0.57]). More than 90% of respondents believed that drug insurance coverage for individual patients was an important factor to consider when deciding to initiate infliximab therapy. Seventy-one per cent of respondents considered provincial funding criteria to be either important or extremely important when deciding whether to initiate infliximab infusions (0.71 [95% CI 0.65 to 0.76]). More than 50% of respondents believed that both the absence of infusion facilities and the absence of trained personnel were important factors to consider when deciding whether to initiate infliximab infusions.
influence of CMe on patterns of infliximab use
The majority of respondents indicated that they participated in CME activities in one or more of the following formats: large groups; expert seminars; review of clinical guidelines; review of medical text books or journals; and consultation with peers. Only 27% indicated that they participated in apprenticeships (clinical observation of an 'expert' clinician or opinion leader in the field). Stratification according to CME activity (defined as respondents who indicated that they 'often' participate in a CME activity) revealed that only apprenticeship seemed to alter the response distribution of specific questionnaire items. Premedication with corticosteroids and the co-administration of IS were both significantly impacted by apprenticeship.
disCussion
The current comprehensive study was the first specifically designed to evaluate the patterns of infliximab use among gastroenterologists. The responses to the survey items suggested that the vast majority of gastroenterologists use infliximab in a similar fashion. High-quality data exist to justify the practice patterns inferred from questionnaire items that elicited the greatest level of participant agreement. However, there was variability in the distribution of responses to selected questionnaire items. One-quarter of respondents were not in agreement with respect to the co-administration of IS therapy. This is meaningful, and likely reflective of the concerns and controversies that currently exist in the scientific community. Recent research has revealed the importance of engaging in medical practices that maximize the duration of effectiveness of the initial anti-TNF biological agent to which an individual is exposed (16) (17) (18) (19) (20) (21) . Data from post hoc subgroup analyses derived from clinical trials, observational studies and, more recently, the results of two large RCTs designed to address this issue (9, 10, 20, 21) have led to confusion and uncertainty with respect to best practice in this area. Despite this, the vast majority of respondents indicated that they would co-administer IS agents with infliximab. This may be reflective, in part, of the influence of Canadian opinion leaders in the field of IBD who have delivered a high volume of CME activities over the past several years. This fact may also explain why respondent participation in apprenticeship CME activities appeared to influence practice patterns. In addition, the past publication of Canadian consensus guidelines pertaining to infliximab use advocated the concomitant use of IS therapy and may have influenced Canadian IBD practice (12) . The uncertain additive benefit of concomitant IS therapy in select patient populations above and beyond scheduled infliximab infusions has also led gastroenterologists to question the additive benefit of corticosteroid premedication. This fact also appears to be reflected in the distribution of responses to questions about the use of corticosteroids as premedication to infliximab. A similar questionnaire designed to evaluate American gastroenterologists' patterns of infliximab use was distributed during a similar time frame. That survey was distributed to gastroenterologists practicing in Maryland and Washington, DC (USA) (22) , with only 28.6% of gastroenterologists responding (96 of 336). The authors inferred that the respondents underused immunomodulators, failed to use maintenance infliximab and had a lack of awareness of major infliximab-related adverse events. However, due to the low response rate, caution must be exercised when interpreting the results of that study given the potential for nonresponse bias. The responses to questions pertaining to strategy on loss of response in primary infliximab responders were not uniform. In general, immunogenical loss of response can be addressed by increasing infliximab dose to 'overwhelm' antibody response, or to decrease infliximab interval to intervene with the next infusion before the trough serum infliximab concentration decreases below known therapeutic levels (17) . In the absence of any high-quality data to support the superiority of one strategy over the other, clinicians have been left to their own devices to deal with such problems. The fact that the majority of respondents indicated that they would decrease the infliximab interval upon loss of response might be reflective of the sense of fiscal responsibility felt by physicians working within the Canadian health care system. Purely from the perspective of pharmaceutical cost, doubling the dose of infliximab would be more expensive than decreasing the infusion interval from eight weeks to six weeks. Most patients who require infliximab in Canada must fulfill a set of criteria for the provincial government to subsidize the cost of the medication (ie, exceptional drug status). Thus, increasing the drug dose significantly increases the cost burden to both the government and the patient. In provinces in which infliximab infusions are provided through private infliximab infusion facilities (now in most provinces in Canada), the direct nonpharmaceutical medical costs associated with infliximab infusions are absorbed by private industry. Although Canadian gastroenterologists may try to decrease the financial burden placed on patients who cannot afford to cover the residual cost of escalating infliximab doses, increasing the frequency of infliximab infusions increases the indirect and societal costs through increased time away from work, lost wages and decreased productivity. The observed differences in the responses to questions pertaining to concomitant IS use, corticosteroid premedication and duration of infliximab therapy among physicians in academic practice versus community-based practice could be explained in several ways. Gastroenterologists in academic practice likely work in close proximity to opinion leaders in the field of IBD and attend IBD educational rounds more frequently. Thus, they may have increased exposure to discussion and debate relating to the utility of steroid premedication and concomitant IS therapy. Similarly, concerns related to the potential long-term effects of prolonged anti-TNF use may be communicated in a more timely manner to gastroenterologists working at academic centres, who have the benefit of listening to visiting experts. The observed influence of 'practice region' on infliximab initiation regimen and on the perceived barriers to infliximab use may be a result of more stringent provincial funding criteria in these regions at the time the survey was conducted.
The results of the present survey suggest that Canadian gastroenterologists practice similarly with respect to the use of infliximab in the management of patients with medically refractory Crohn's disease.
Contradiction and uncertainty in the medical literature appears to be mirrored in the clinical practice of gastroenterologists when it comes to particular aspects of managing medically refractory Crohn's disease with infliximab. The results of the present study will assist gastrointestinal educational governing bodies in the development of specific and targeted educational programs, and underscore the need for high-quality RCTs that serve to further define best strategies in the use of biologicals for the treatment of patients with IBD. These results will also help the Canadian clinical research community identify relevant topics pertaining to the medical management of IBD for future research. 
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